The PROVE-1 and PROVE-2 trials had almost mind-boggling complexity because there were so many treatment arms and protocols (#msg-11248731, #msg-28746843). To sift through this complexity, I’ve condensed the data into a form that is simple to understand yet accurate enough for investment purposes.
• The starting point for the calculations below is the set of all PROVE-1/PROVE-2 patients who were treated with 12 weeks of Telaprevir followed by 12 weeks of SoC.
• Deduct the 17% of patients who discontinued treatment due to adverse events or were lost to follow-up, leaving 83% of the initial patients.
• From the above, deduct the 10% of patients who never achieved undetectable virus, leaving 75% of the original patients.
• From the above, deduct the 2% of patents who experienced a viral breakthrough on treatment, leaving 73% of the original patients. These are the patients who had undetectable virus at the end of 24 weeks of treatment.
• From the above, deduct the 11% of patients who relapsed after stopping treatment, leaving 65% of the original patients who had an SVR. This was an improvement of 20 percentage points vs the 45% SVR rate in the PROVE-1/2 SoC 48-week control arms.
(Patients in PROVE-1/2 who did not achieve an RVR [undetectable virus at week 4] stopped Telaprevir and completed a total of 48 weeks of treatment with the remainder of the 48 weeks on SoC. Although a small number of these patients achieved an SVR after 48 weeks of treatment, they are not included in the 65% figure above.)
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.